Gilead Sciences Inc (GILD) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Over the past 4 years, Gilead Sciences Inc has achieved a revenue compound annual growth rate (CAGR) of 2.1%, while earnings have grown at 10.7% CAGR.
Historical revenue and profitability trends for Gilead Sciences Inc
The chart above illustrates Gilead Sciences Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Gilead Sciences Inc's business.
How efficiently Gilead Sciences Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Gilead Sciences Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Gilead Sciences Inc to continue growing earnings in the coming year. The consensus analyst rating is 4.1333 based on 30 analysts.
Based on our comprehensive analysis, Gilead Sciences Inc (GILD) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Gilead Sciences Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Gilead Sciences Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: GILD Valuation, GILD Dividend, GILD Financial Health
Compare: GILD vs AAPL, GILD vs MSFT, GILD vs GOOGL